Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $17.00.

VIR has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd.

Insiders Place Their Bets

In other Vir Biotechnology news, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $5.93, for a total transaction of $130,460.00. Following the transaction, the director owned 1,166,391 shares of the company’s stock, valued at $6,916,698.63. The trade was a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $5.98, for a total value of $1,147,286.92. Following the completion of the transaction, the insider owned 13,728,924 shares in the company, valued at $82,098,965.52. This represents a 1.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 921,608 shares of company stock worth $5,711,957. 16.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vir Biotechnology

Institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology in the second quarter worth $35,000. FNY Investment Advisers LLC purchased a new position in Vir Biotechnology in the third quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. increased its position in Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares in the last quarter. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Vir Biotechnology during the 2nd quarter valued at about $50,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Stock Up 2.8%

Shares of NASDAQ VIR opened at $7.78 on Friday. Vir Biotechnology has a 12 month low of $4.16 and a 12 month high of $11.00. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -2.16 and a beta of 1.39. The business has a fifty day simple moving average of $6.36 and a 200-day simple moving average of $5.69.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. During the same quarter in the previous year, the firm posted ($1.56) EPS. Vir Biotechnology’s quarterly revenue was up .8% on a year-over-year basis. As a group, sell-side analysts expect that Vir Biotechnology will post -3.92 EPS for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.